Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -73.47%
Price change 2022 → 2023: -13.85%
Price change 2023 → 2024: -52.23%
Price change 2024 → 2025: -48.88%
Price change 2025 → 2026: 20.48%
Price change 2026 (year to date): 13.82%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.87
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -0.40
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 0.00% from the high over 6 months.
Insufficient correction (< 10.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="BOLT" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Bolt Biotherapeutics, Inc. | – | 0.87 | – | 🔒 |
| Femasys Inc. | – | 0.80 | +16.2 % | – |
| Geratherm Medical AG | – | 0.13 | −1.2 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Bolt Biotherapeutics, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2020 | 231,000 | -60.7 m | -26,289.2 % | n/a |
| 2021 | 1.3 m | -98.6 m | -7,824.7 % | +445.5 % |
| 2022 | 5.7 m | -88.1 m | -1,537.8 % | +354.7 % |
| 2023 | 7.9 m | -69.2 m | -878.6 % | +37.5 % |
| 2024 | 7.7 m | -63.1 m | -820.8 % | -2.4 % |
| 2025 | 7.7 m | -33.4 m | -433.7 % | +0.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 20/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Bolt Biotherapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 186 m | 169 m | 102 m | 47.3 m | 27.5 m |
| Total Debt | 24.4 m | 22.6 m | 20.2 m | 25.2 m | 23.0 m |
| Net Debt | -3.0 m | 13.4 m | 9.4 m | 18.0 m | 11.3 m |
| Equity | 250 m | 172 m | 113 m | 57.2 m | 26.5 m |
| Total assets | 308 m | 228 m | 160 m | 99.6 m | 56.7 m |
| Operating cash flow | -57.1 m | -76.5 m | -69.5 m | -61.3 m | -39.9 m |
| Investments (capex) | 2.3 m | 2.0 m | 206,000 | 41,000 | 72,000 |
| Free cash-flow | -59.4 m | -78.5 m | -69.7 m | -61.3 m | -39.9 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 21/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Bolt Biotherapeutics, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in Bolt Biotherapeutics, Inc.
Large funds tracked
| Fund | Shares | Value (USD) | Weight in the fund | Change | Quarter |
|---|---|---|---|---|---|
| Citadel Advisors | 113,806 | 438,154 | 0.0 % | +1,025.8 % | 2026Q2 |
| Renaissance Technologies | 98,625 | 379,706 | 0.0 % | +27.7 % | 2026Q2 |
| Geode Capital Management | 19,119 | 73,622 | 0.0 % | -33.6 % | 2026Q2 |
| Vanguard Group | 10,179 | 55,782 | 0.0 % | -70.3 % | 2025Q4 |
| BlackRock | 9,711 | 37,388 | 0.0 % | 0.0 % | 2026Q2 |
| Morgan Stanley | 3,145 | 12,108 | 0.0 % | -1.4 % | 2026Q2 |
| JPMorgan Chase | 42 | 165 | 0.0 % | 0.0 % | 2026Q2 |
Latest insider transactions
| Date | Person | Side | Amount |
|---|---|---|---|
| 17/11/2026 | Coastlands Capital Lp | purchase | 114,998 USD |
| 16/11/2026 | Coastlands Capital Lp | purchase | 194,924 USD |
| 09/11/2026 | Coastlands Capital Lp | purchase | 319,000 USD |
| 18/09/2026 | Yonehiro Grant | sale | 22,169 USD |
| 18/09/2026 | Nemec Sarah | sale | 13,195 USD |
| 18/09/2026 | Quinn William P. | sale | 29,555 USD |
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 21/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Bolt Biotherapeutics, Inc.
What is the Bolt Biotherapeutics, Inc. share price?
Latest recorded price: 4.91 USD on 20/11/2026, for a market cap of 12.8 m USD.
What is the revenue of Bolt Biotherapeutics, Inc.?
7.7 m USD for fiscal year 2025, with net income of -33.4 m USD (net margin -433.7 %).
What do analysts say about Bolt Biotherapeutics, Inc.?
Out of 8 analysts: 3 buy or strong buy, 5 hold, 0 sell or strong sell.
Is Bolt Biotherapeutics, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0977022039).
How many employees does Bolt Biotherapeutics, Inc. have?
52 full-time employees according to the latest published profile.
Who runs Bolt Biotherapeutics, Inc.?
William P. Quinn is the company's chief executive.
Which large funds own Bolt Biotherapeutics, Inc.?
As of 2026Q2, among the large funds tracked: Citadel Advisors, Renaissance Technologies, Geode Capital Management, Vanguard Group, BlackRock.